wisconsin.gov HomeState AgenciesDepartment of Health Services
Welcome  » January 27, 2026 3:44 PM
Login
Search

Sickle Cell Disease Cell and Gene Therapy Resources

The Wisconsin Department of Health Services (DHS) is participating in the Centers for Medicare & Medicaid Services’ (CMS’) Cell and Gene Therapy Access Model. This model allows DHS to enter into enhanced rebate agreements with the manufacturers of two State-Selected Model Drugs, Casgevy and Lyfgenia.

Resources

ForwardHealth Resources

  • ForwardHealth Update 2025-37, “Changes for Casgevy and Lyfgenia and Other Policies in the New Cell and Gene Therapy Access Model for Members With Sickle Cell Disease”
  • ForwardHealth Online Handbook:
    • Disenrollment and Exemptions topic #392
    • Covered Outpatient Drug Reimbursement topic #1351
    • Casgevy topic #23658
    • Lyfgenia topic #23657
    • Cell and Gene Therapy Access Model topic #24044
  • FAQs About Cell and Gene Access Model

 

Federal Resources

Wisconsin Resources

Non-Governmental Resources

 

 

 

 

 
 
About  |  Contact |  Disclaimer  |  Privacy Notice
Wisconsin Department of Health Services
Production PROD_WIPortal2_M1039A__7
Browser Tab ID: 1   -1